Table 3 Influence of acne-like skin rash on tumour response and survival

From: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

Tumour response

# of patients (%)

P -value

Grade 0-1-2

6/39 (10.25%)

0.006

Grade 3

8/16 (62.5%)

 

TTP

Median TTP (95% C.I.) in months

P-value

Grade 0-1-2

4.00 (3.6–4.4)

0.007

Grade 3

6.00 (5.3–6.7)

 

OS

Median OS (95% C.I.) in months

P-value

Grade 0-1-2

9.1 (4.1–9.7)

0.06

Grade 3

10.3 (3.9–11.3)

 
  1. TTP: time to progression; OS: overall survival; 95% C.I.: 95% confidence interval.
Back to article page